Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients

Pediatric Hematology and Oncology

Volumn 28, Issue 6, 2011, Pages 461-468

  Durmaz, Oguzhan ^a   Demirkaya, Metin ^a   Sevinir, Betl ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Anemia; erythropoietin; quality of life; survival

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN BETA; UNCLASSIFIED DRUG;

ADOLESCENT; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPEREMIA; INJECTION SITE PAIN; LYMPHOMA; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; QUALITY OF LIFE; SCHOOL CHILD; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; ERYTHROPOIETIN; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; MALE; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOMBINANT PROTEINS; SURVIVAL RATE; TIME FACTORS;

EID: 80051966164     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.570857     Document Type: Article

References (19)

1. Feusner J, Hastings C. Recombinant human erythropoietin in pediatric oncology: a review. Med Pediatr Oncol. 2002;39:463-468. (Pubitemid 34976950)
2. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol. 2006;3:152-164.
3. Oberhoff C. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins. Support Care Cancer. 2007;15:603-611. (Pubitemid 47034989)
4. Erslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol. 2000;64:353-358. (Pubitemid 30435387)
5. Marec-Berard P, Chastagner P, Kassab-Chahmi D, et al. 2007 standarts, options, and recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for themanagement of anemia in children with cancer. Pediatr Blood Cancer. 2009;53:7-12.
6. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol. 2008;26:132-149.
7. Lansky SB, List MA, Lansky LL, et al. The measurement of performance in childhood cancer patients. Cancer 1987;60:1651-1656. (Pubitemid 17141022)
8. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84:3-10. (Pubitemid 32453429)
9. Büyükpamukçu M, Varan A, Kutluk T, Akyüz C. Is epoetin alfa a treatment option for chemotherapyrelated anemia in children? Med Pediatr Oncol. 2002;39:455-458.
10. Zoubek A, Kronberger M. Early epoetin alfa treatment in children with solid tumors. Med Pediatr Oncol. 2002;39:459-462. (Pubitemid 34976949)
11. Yilmaz D, Cetingül N, Kantar M, et al. A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr Hematol Oncol. 2004;21:1-8. (Pubitemid 38101404)
12. Razzouk BI, Hord JD, Hockenberry M, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006;24:3583-3589. (Pubitemid 46630530)
13. Abdelrazik N, Fouda M. Once weekly recombinant human erythropoietin treatment for cancerinduced anemia in children with acute lymphoblastic leukemia receivingmaintenance chemotherapy: a randomized case-controlled study. Hematology. 2007;12:533-541. (Pubitemid 350048064)
14. Corapcioglu F, Aksu G, Basar EZ, et al. Recombinant human erythropoietin beta therapy: an effective strategy reduce transfusion requirement in children receiving anticancer treatment. Pediatr Hematol Oncol. 2008;25:509-521.
15. Varan A, Büyükpamukçu M, Kutluk T, Akyüz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics. 1999;103:E16-E19.
16. Kronberger M, Fischmeister G, Poetschger U, et al. Reduction in transfusion requirementswith early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study. Pediatr Hematol Oncol. 2002;19:95-105. (Pubitemid 34665504)
17. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updatedmeta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-714. (Pubitemid 43821788)
18. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005;97:489-498. (Pubitemid 40590430)
19. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.